adverse events

October 15, 2020October 15, 2020

Gene Variants May Predict Adverse MTX Treatment Outcome in JIA Patients

News

Variations in single nucleotides — the building blocks of DNA — in two genes may help predict the safety and efficacy of methotrexate (MTX) treatment in individual children with juvenile idiopathic ... Read more

August 30, 2019August 30, 2019

Infections Rare in JIA Children Treated with Biological Agents, Study Finds

News

Developing infections as a side effect of juvenile idiopathic arthritis treatment with biological agents is rare — and in most cases, such infections are either mild or moderate in severity, ... Read more

September 7, 2018September 7, 2018

Humira’s Safety in Children With JA, Other Diseases Comparable to That in Adults, Study Suggests

News

The safety profile of Humira (adalimumab) in children with polyarticular juvenile idiopathic arthritis (pJIA), enthesitis-related arthritis, and Crohn’s disease is similar to that in adults, a large analysis of multiple ... Read more

August 24, 2018August 24, 2018

Actemra, Kineret Have Similar One-Year Efficacy in sJIA Patients, Study Finds

News

Treatment of systemic juvenile idiopathic arthritis (sJIA) with either the approved therapy Actemra (tocilizumab) or Kineret (anakinra, not yet approved for sJIA) led to similar effectiveness after one year, according to a new ... Read more

March 23, 2018March 23, 2018

Longer Inactive JIA Disease Before Stopping MTX Reduces Risk of Flares, Study Finds

News

Juvenile idiopathic arthritis (JIA) patients who spend longer periods without disease worsening before discontinuing methotrexate (MTX) treatment have significantly lower flare rates, a German study reports. In the study, “Time ... Read more